Mankind, IPCA, Torrent, Ajanta, Sun Lead Pharma Market Growth In November
The Indian pharmaceutical market grew over the preceding month in November amid recovering sales.
India's pharmaceutical market grew in November as sales recovered, aided by drugs used for chronic conditions from diabetes to heart diseases.
The pharma industry value rose 6.6% year-on-year last month, Motilal Oswal said in a report. That compares with a 5% rise in October and 1% growth in November 2020, it said.
India Ratings and Research Pvt. attributed the trend to rising sales in the chronic therapy segment. "Volumes were flat year-on-year, while price growth was at 5.4%. New product launches' value grew 1.2%, driven by acute therapy or drugs for short-term ailments and emergencies.
Based on data from All-India Origin Chemists & Distributors Ltd. cited by India Ratings:
The chronic segment grew the most at 7.2% over a year earlier with a market share of 33%.
The sub-chronic segment's value rose 6.7% with a market share of 20%.
The acute therapy grew 6% with a share of 47%.
Sales of non-Covid drugs rose 6.7% year-on-year in November, while that of Covid therapies rose 6.3%, according to Motilal Oswal.
According to the AIOCD data:
Sales of acute therapies such as gastro, respiratory and pain/analgesics rose 13.1%, 16.3% and 17.3%, respectively.
Anti-infectives' sales contracted 1.1%.
Chronic therapy sales of cardiac and anti-diabetic drugs rose 6.3% and 6%, respectively.
The moving annual total, or 12-month rolling sales, of pharmaceutical products in the country rose 15.2% in November.
Sales of vaccines fell 12.5% year-on-year, impacting the overall MAT growth, Motilal Oswal said.
According to the brokerage:
These companies grew more than the industry average: Mankind Pharma Ltd., IPCA Laboratories Ltd., Torrent Pharmaceuticals Ltd., Ajanta Pharma Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Aristo Pharmaceuticals Pvt., Eris Lifesciences Ltd., Micro Labs Ltd. and Intas Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd.'s sales fell 18% year-on-year amid a decline in demand for Covid therapies as new infections dropped.